Media is too big
VIEW IN TELEGRAM
Triall AMA: Did you catch our last session? 📺💬
In our last community AMA, Triall co-founder Joost talks about how the utility of $TRL will evolve and expand over time with the introduction of new products & services.
Missed the live session?
👉 Check the full recording: youtube.com/live/aLSPeWAuKdo?si=6aaJed3hOipxpT6J
⚡️ Trade $TRL at bit.ly/tradeTRL
🗣 Help spread the news:
https://x.com/triallofficial/status/1712077793045983527?s=20
#blockchainforhealth #TRL
In our last community AMA, Triall co-founder Joost talks about how the utility of $TRL will evolve and expand over time with the introduction of new products & services.
Missed the live session?
👉 Check the full recording: youtube.com/live/aLSPeWAuKdo?si=6aaJed3hOipxpT6J
⚡️ Trade $TRL at bit.ly/tradeTRL
🗣 Help spread the news:
https://x.com/triallofficial/status/1712077793045983527?s=20
#blockchainforhealth #TRL
Data-informed clinical research: zooming in on external control arms 🔍
Recent advancements in data science & technology have made way for a new virtual counterpart to the control group.
These ‘external control arms’ draw data from historical clinical trials or RWD sources like electronic health records.
They offer a solution for scenarios where recruiting a control arm is not feasible, for instance in the case of rare or life-threatening conditions with no or inadequate treatment options.
Research suggests external control arms can reduce sample size requirements by up to 20-50%, leading to significant cost-savings while also speeding up recruitment timelines.
In this article, we cover FDA guidance on externally controlled trials and 2 biopharma companies that successfully applied this approach.
👉 Link: triall.io/articles/beyond-randomised-controlled-trials-how-external-control-arms-could-change-the-game
🗣 Help spread the news:
x.com/triallofficial/status/1712441092077916338?s=20
Recent advancements in data science & technology have made way for a new virtual counterpart to the control group.
These ‘external control arms’ draw data from historical clinical trials or RWD sources like electronic health records.
They offer a solution for scenarios where recruiting a control arm is not feasible, for instance in the case of rare or life-threatening conditions with no or inadequate treatment options.
Research suggests external control arms can reduce sample size requirements by up to 20-50%, leading to significant cost-savings while also speeding up recruitment timelines.
In this article, we cover FDA guidance on externally controlled trials and 2 biopharma companies that successfully applied this approach.
👉 Link: triall.io/articles/beyond-randomised-controlled-trials-how-external-control-arms-could-change-the-game
🗣 Help spread the news:
x.com/triallofficial/status/1712441092077916338?s=20
Triall AMA: Announcing the winners 🏆📺💬
Wow! In our 16th AMA session, the Triall community submitted a record number of over 250 questions for the team.
We’d like to thank all who took the time to submit questions using our Q&A portal.
Now, we’re thrilled to announce the winners.
AMA winner list
@xiaoxizii
@kieule0701
@Concutrangxoa
@andypham72
@Commenaudin
How do I redeem my reward?
Please contact @rxvdwaal to share your BEP-20 address.
Missed the live session?
Check out the full recording: youtube.com/watch?v=aLSPeWAuKdo
When is the next AMA?
Our next community AMA will be hosted in a couple of weeks (date TBA).
🗣 Help spread the news:
https://x.com/triallofficial/status/1712786630912700497?s=20
#blockchainforhealth #TRL
Wow! In our 16th AMA session, the Triall community submitted a record number of over 250 questions for the team.
We’d like to thank all who took the time to submit questions using our Q&A portal.
Now, we’re thrilled to announce the winners.
AMA winner list
@xiaoxizii
@kieule0701
@Concutrangxoa
@andypham72
@Commenaudin
How do I redeem my reward?
Please contact @rxvdwaal to share your BEP-20 address.
Missed the live session?
Check out the full recording: youtube.com/watch?v=aLSPeWAuKdo
When is the next AMA?
Our next community AMA will be hosted in a couple of weeks (date TBA).
🗣 Help spread the news:
https://x.com/triallofficial/status/1712786630912700497?s=20
#blockchainforhealth #TRL
Triall Insights 🔍
Over 75% of clinical trial protocols require at least one substantial amendment, with the highest observed prevalence (89%) in Phase 2 studies
Protocol amendments are highly disruptive and represent the largest cause of unplanned delays and unbudgeted costs in clinical trials.
Source: csdd.tufts.edu/impact-reports
⚡️ Trade $TRL at bit.ly/tradeTRL
🗣️ Help us spread the news:
https://x.com/triallofficial/status/1713885182057423117?s=20
#blockchainforhealth #TRL
Over 75% of clinical trial protocols require at least one substantial amendment, with the highest observed prevalence (89%) in Phase 2 studies
Protocol amendments are highly disruptive and represent the largest cause of unplanned delays and unbudgeted costs in clinical trials.
Source: csdd.tufts.edu/impact-reports
⚡️ Trade $TRL at bit.ly/tradeTRL
🗣️ Help us spread the news:
https://x.com/triallofficial/status/1713885182057423117?s=20
#blockchainforhealth #TRL
Just in: research on key bottlenecks in clinical trial setup & conduct 🗞️
Clinical trials are often delayed, making it hard for sponsors to budget & timeframe their clinical development.
The list of possible reasons for delays is long, but not all factors are equally impactful on timelines.
Researchers at Witten/Herdecke University therefore conducted a critical path analysis to identify the most prominent bottlenecks in clinical trials.
The researchers identified protocol development, IMP supply, site contracting, and patient recruitment as the most critical.
To avoid bottlenecks in these activities, sponsors should:
(1) plan with buffer time
(2) build governance frameworks
(3) adopt agile working models
(4) leverage novel technologies accelerating processes
(5) pay attention to improved communication & coordination
🔗 Article link: doi.org/10.1016/j.drudis.2023.103733
🗣️ Help us spread the news:
x.com/triallofficial/status/1714600440187240794?s=20
#blockchainforhealth #TRL
Clinical trials are often delayed, making it hard for sponsors to budget & timeframe their clinical development.
The list of possible reasons for delays is long, but not all factors are equally impactful on timelines.
Researchers at Witten/Herdecke University therefore conducted a critical path analysis to identify the most prominent bottlenecks in clinical trials.
The researchers identified protocol development, IMP supply, site contracting, and patient recruitment as the most critical.
To avoid bottlenecks in these activities, sponsors should:
(1) plan with buffer time
(2) build governance frameworks
(3) adopt agile working models
(4) leverage novel technologies accelerating processes
(5) pay attention to improved communication & coordination
🔗 Article link: doi.org/10.1016/j.drudis.2023.103733
🗣️ Help us spread the news:
x.com/triallofficial/status/1714600440187240794?s=20
#blockchainforhealth #TRL
Triall Announcements
Just in: research on key bottlenecks in clinical trial setup & conduct 🗞️ Clinical trials are often delayed, making it hard for sponsors to budget & timeframe their clinical development. The list of possible reasons for delays is long, but not all factors…
Triall Insights 🔍
According to the IQVIA Institute, over 960 next-generation biotherapeutics are currently in development (Phase I through regulatory submission).
These include cell therapies, gene therapies, gene editing, nucleotide and RNA interference, mRNA therapies, and RNA or DNA vaccines.
More than 40% of these next-generation biotherapeutics in development focus on oncology, bringing great promise for cancer treatment.
Source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-trends-in-r-and-d-2023
🗣️ Help us spread the news:
https://x.com/triallofficial/status/1716411121383473439?s=20
#blockchainforhealth #TRL
According to the IQVIA Institute, over 960 next-generation biotherapeutics are currently in development (Phase I through regulatory submission).
These include cell therapies, gene therapies, gene editing, nucleotide and RNA interference, mRNA therapies, and RNA or DNA vaccines.
More than 40% of these next-generation biotherapeutics in development focus on oncology, bringing great promise for cancer treatment.
Source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-trends-in-r-and-d-2023
🗣️ Help us spread the news:
https://x.com/triallofficial/status/1716411121383473439?s=20
#blockchainforhealth #TRL
Media is too big
VIEW IN TELEGRAM
Triall AMA: Did you catch our last session? 📺💬
In our last community AMA, Triall co-founder Ray talks about the promises of dynamic consent in clinical research and the enabling role of blockchain and SSI technologies.
Missed the live session?
👉 Check the full recording: youtube.com/watch?v=aLSPeWAuKdo
⚡️ Trade $TRL at bit.ly/tradeTRL
🗣 Help spread the news:
https://x.com/triallofficial/status/1717140655913242691?s=20
#blockchainforhealth #TRL
In our last community AMA, Triall co-founder Ray talks about the promises of dynamic consent in clinical research and the enabling role of blockchain and SSI technologies.
Missed the live session?
👉 Check the full recording: youtube.com/watch?v=aLSPeWAuKdo
⚡️ Trade $TRL at bit.ly/tradeTRL
🗣 Help spread the news:
https://x.com/triallofficial/status/1717140655913242691?s=20
#blockchainforhealth #TRL
Triall Insights 🔍
According to the IQVIA Institute, the past 5 years has seen a significant number of first-in-class medicines.
In 2022, 62% of launches included first-in-class therapies (spread across nearly all major therapeutic areas), reflecting the increasing availability of novel science for patients.
Source: iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-trends-in-r-and-d-2023
🗣️ Help us spread the news:
https://x.com/triallofficial/status/1718970891608973399?s=20
#blockchainforhealth #TRL
According to the IQVIA Institute, the past 5 years has seen a significant number of first-in-class medicines.
In 2022, 62% of launches included first-in-class therapies (spread across nearly all major therapeutic areas), reflecting the increasing availability of novel science for patients.
Source: iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-trends-in-r-and-d-2023
🗣️ Help us spread the news:
https://x.com/triallofficial/status/1718970891608973399?s=20
#blockchainforhealth #TRL
Moving beyond randomised controlled trials 🔍
Randomised controlled trials (RCTs) are widely regarded as the “gold standard” of clinical research.
Praised for their scientific rigour & statistical robustness, RCTs facilitate unbiased evaluation of treatment efficacy & safety.
RCTs are, however, not always feasible, especially when the target patient population is hard to come by.
With 30% of global drug development pipelines targeting rare diseases, the need for novel methods is pivotal.
One such method is the external control arm, a virtual alternative to the traditional concurrent control group.
In this article, we unpack the promise of this novel method, covering recent FDA guidance on externally controlled trials as well as two recent biopharma success stories.
👉 Link: triall.io/articles/beyond-randomised-controlled-trials-how-external-control-arms-could-change-the-game
🗣 Help spread the news:
x.com/triallofficial/status/1720056468580258214?s=20
#blockchainforhealth #TRL
Randomised controlled trials (RCTs) are widely regarded as the “gold standard” of clinical research.
Praised for their scientific rigour & statistical robustness, RCTs facilitate unbiased evaluation of treatment efficacy & safety.
RCTs are, however, not always feasible, especially when the target patient population is hard to come by.
With 30% of global drug development pipelines targeting rare diseases, the need for novel methods is pivotal.
One such method is the external control arm, a virtual alternative to the traditional concurrent control group.
In this article, we unpack the promise of this novel method, covering recent FDA guidance on externally controlled trials as well as two recent biopharma success stories.
👉 Link: triall.io/articles/beyond-randomised-controlled-trials-how-external-control-arms-could-change-the-game
🗣 Help spread the news:
x.com/triallofficial/status/1720056468580258214?s=20
#blockchainforhealth #TRL
Triall Insights 🔍
Biotech therapies are on the rise.
According to Tufts CSDD, the number of biotech products in late-stage clinical trials has quadrupled during the past decade.
There are currently 594 novel biotech products, 146 marketed products, and 192 biosimilars in Phase 3 clinical trials.
Source: csdd.tufts.edu/impact-reports
🗣️ Help us spread the news:
https://x.com/triallofficial/status/1721498926207979987?s=20
#blockchainforhealth #TRL
Biotech therapies are on the rise.
According to Tufts CSDD, the number of biotech products in late-stage clinical trials has quadrupled during the past decade.
There are currently 594 novel biotech products, 146 marketed products, and 192 biosimilars in Phase 3 clinical trials.
Source: csdd.tufts.edu/impact-reports
🗣️ Help us spread the news:
https://x.com/triallofficial/status/1721498926207979987?s=20
#blockchainforhealth #TRL
Triall listed in the State of European HealthTech 2023 by AlbionVC 📢
UK-based venture capital firm AlbionVC has included Triall in its 3rd annual version of the European #healthtech market map.
The report includes a total of 998 companies across the digital pharma and digital care domains.
👁 View the full map including insights on emerging trends, methodology, and sector segmentation: albion.vc/spotlight/deep-dives/european-healthtech-market-map-2023/
🗣️ Help us spread the news:
https://x.com/triallofficial/status/1722270268138418340?s=20
#blockchainforhealth #TRL
UK-based venture capital firm AlbionVC has included Triall in its 3rd annual version of the European #healthtech market map.
The report includes a total of 998 companies across the digital pharma and digital care domains.
👁 View the full map including insights on emerging trends, methodology, and sector segmentation: albion.vc/spotlight/deep-dives/european-healthtech-market-map-2023/
🗣️ Help us spread the news:
https://x.com/triallofficial/status/1722270268138418340?s=20
#blockchainforhealth #TRL
Decoding data-informed protocol development 🤖
The past decade has seen an upward trend in the scientific & executional complexity of clinical trial protocols, often leading to unexpected delays & unbudgeted costs.
To answer this issue, sponsors & CROs are increasingly looking at historical data to inform their study designs and thereby promote the predictability & cost-efficiency of their studies.
This trend has been driven by advancements in data analytics, predictive modelling, and #AI as well as the increasing availability of #RWD and historical clinical trial data.
In this article, we dive into the key benefits & implementation drivers of data-informed protocol development.
We discuss how historical data is successfully being used to make clinical trials more adaptable, cost-efficient, and patient-centric.
👉 Full article: triall.io/articles/data-informed-protocol-development
🗣️ Help us spread the news:
https://x.com/triallofficial/status/1722602351394238623?s=20
#blockchainforhealth #TRL
The past decade has seen an upward trend in the scientific & executional complexity of clinical trial protocols, often leading to unexpected delays & unbudgeted costs.
To answer this issue, sponsors & CROs are increasingly looking at historical data to inform their study designs and thereby promote the predictability & cost-efficiency of their studies.
This trend has been driven by advancements in data analytics, predictive modelling, and #AI as well as the increasing availability of #RWD and historical clinical trial data.
In this article, we dive into the key benefits & implementation drivers of data-informed protocol development.
We discuss how historical data is successfully being used to make clinical trials more adaptable, cost-efficient, and patient-centric.
👉 Full article: triall.io/articles/data-informed-protocol-development
🗣️ Help us spread the news:
https://x.com/triallofficial/status/1722602351394238623?s=20
#blockchainforhealth #TRL
Triall Insights 🔍
According to IQVIA, more than 2,000 oncology products are currently under development.
71% of these products are coming from emerging biopharma companies (up from 45% a decade ago), signalling a decrease in reliance on Big Pharma.
Source: iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-oncology-trends-2023
🗣️ Help spread the news:
https://x.com/triallofficial/status/1724040950274531622?s=20
#blockchainforhealth #TRL
According to IQVIA, more than 2,000 oncology products are currently under development.
71% of these products are coming from emerging biopharma companies (up from 45% a decade ago), signalling a decrease in reliance on Big Pharma.
Source: iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-oncology-trends-2023
🗣️ Help spread the news:
https://x.com/triallofficial/status/1724040950274531622?s=20
#blockchainforhealth #TRL
Zooming in on novel trial designs 🔬
Novel trial designs have seen a dramatic uptake from just 7.5% of studies in 2010 to 17.0% in 2022.
Let’s dive into the 4 most common types:
☂️ Umbrella trials: Test the effect of multiple therapies in a single disease. Patients with the same indication are segmented into subgroups based on their specific biomarkers or genetic profile.
🗑️ Basket trials: Test a single therapy across different disease types that share a common biomarker. Focus on a specific molecular target or pathway rather than disease.
🌐 Master Protocols: Comprehensive frameworks that guide multiple clinical trials under a single, overarching design. Enable the simultaneous investigation of various interventions in different sub-studies.
⚙️ Adaptive Protocols: Flexible trial designs that permit modifications based on real-time data analysis. Changes might include adjustments to sample sizes, treatment regimens, or new patient groups.
🗣️https://x.com/triallofficial/status/1725122264717218277?s=20
Novel trial designs have seen a dramatic uptake from just 7.5% of studies in 2010 to 17.0% in 2022.
Let’s dive into the 4 most common types:
☂️ Umbrella trials: Test the effect of multiple therapies in a single disease. Patients with the same indication are segmented into subgroups based on their specific biomarkers or genetic profile.
🗑️ Basket trials: Test a single therapy across different disease types that share a common biomarker. Focus on a specific molecular target or pathway rather than disease.
🌐 Master Protocols: Comprehensive frameworks that guide multiple clinical trials under a single, overarching design. Enable the simultaneous investigation of various interventions in different sub-studies.
⚙️ Adaptive Protocols: Flexible trial designs that permit modifications based on real-time data analysis. Changes might include adjustments to sample sizes, treatment regimens, or new patient groups.
🗣️https://x.com/triallofficial/status/1725122264717218277?s=20
Triall Insights 🔍
Composite success rates in oncology clinical trials have been trending downward since 2015, falling to 3.5% in 2022.
This decline reflects the complex nature of cancer research, which knows one of the lowest success rates among all therapeutic areas.
Success rates are however highly variable across oncology products, with rare and haematological cancer products seeing higher success on average compared to non-rare and solid tumour cancers.
Source: iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-oncology-trends-2023
🗣️ Help spread the news:
https://x.com/triallofficial/status/1726582443430535290?s=20
#blockchainforhealth #TRL
Composite success rates in oncology clinical trials have been trending downward since 2015, falling to 3.5% in 2022.
This decline reflects the complex nature of cancer research, which knows one of the lowest success rates among all therapeutic areas.
Success rates are however highly variable across oncology products, with rare and haematological cancer products seeing higher success on average compared to non-rare and solid tumour cancers.
Source: iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-oncology-trends-2023
🗣️ Help spread the news:
https://x.com/triallofficial/status/1726582443430535290?s=20
#blockchainforhealth #TRL
Should clinical trial participants own their data? 👩💻
Data ownership has been a topic of frequent debate among clinical trial stakeholders.
Historically, consensus has been that clinical trial data is owned by the sponsor and that there’s no requirement to share individual research data with participants after a study.
However, the past years have seen a surge in initiatives that are challenging this status quo.
👇🧵 In this Twitter thread we dive into some high-profile examples:
https://x.com/triallofficial/status/1728024257844641952?s=20
#blockchainforhealth #TRL
Data ownership has been a topic of frequent debate among clinical trial stakeholders.
Historically, consensus has been that clinical trial data is owned by the sponsor and that there’s no requirement to share individual research data with participants after a study.
However, the past years have seen a surge in initiatives that are challenging this status quo.
👇🧵 In this Twitter thread we dive into some high-profile examples:
https://x.com/triallofficial/status/1728024257844641952?s=20
#blockchainforhealth #TRL
Triall Announcements
Triall Insights 🔍 Composite success rates in oncology clinical trials have been trending downward since 2015, falling to 3.5% in 2022. This decline reflects the complex nature of cancer research, which knows one of the lowest success rates among all therapeutic…
Triall Insights 🔍
Patient organisations play an increasingly important role in clinical research and care.
For instance, patient organisations now provide input into 21% of drug health technology assessments (#HTA) globally, reaching as high as 52% in fields such as oncology in the EU and commonwealth countries, places where patient input is most frequently requested.
Countries seek input from patient organisations to better understand the perspectives of patients and caregivers, including the impact of medicines on daily lives and functioning as well as their potential to enhance quality or length of life.
Source: iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/supporting-patients-through-research-collaboration
🗣️ Help spread the news:
https://x.com/triallofficial/status/1729124934570447311?s=20
#blockchainforhealth #TRL
Patient organisations play an increasingly important role in clinical research and care.
For instance, patient organisations now provide input into 21% of drug health technology assessments (#HTA) globally, reaching as high as 52% in fields such as oncology in the EU and commonwealth countries, places where patient input is most frequently requested.
Countries seek input from patient organisations to better understand the perspectives of patients and caregivers, including the impact of medicines on daily lives and functioning as well as their potential to enhance quality or length of life.
Source: iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/supporting-patients-through-research-collaboration
🗣️ Help spread the news:
https://x.com/triallofficial/status/1729124934570447311?s=20
#blockchainforhealth #TRL
Connecting Web3, AI, and medical research 🤖
Andreessen Horowitz recently published a follow-on to its annual State of Crypto report.
It covers the why, what, and how of Web3, presents relevant adoption data, and offers guiding principles to policy makers for consumer protection, compliance & innovation.
👇🧵In this Twitter thread we dive into key findings relevant to Triall, medical research, and #DeSci:
https://x.com/triallofficial/status/1729844578088358034?s=20
#blockchainforhealth #TRL
Andreessen Horowitz recently published a follow-on to its annual State of Crypto report.
It covers the why, what, and how of Web3, presents relevant adoption data, and offers guiding principles to policy makers for consumer protection, compliance & innovation.
👇🧵In this Twitter thread we dive into key findings relevant to Triall, medical research, and #DeSci:
https://x.com/triallofficial/status/1729844578088358034?s=20
#blockchainforhealth #TRL
Triall Insights 🔍
Biotech is on the rise.
Since 2021, 60% of novel therapies approved by the FDA are biotech products.
Moreover, global sales of biotech products have consistently increased since 2018, surpassing $466 billion in 2022.
Source: csdd.tufts.edu/impact-reports
🗣️ Help us spread the news:
https://x.com/triallofficial/status/1731655589191713253?s=20
#blockchainforhealth #TRL
Biotech is on the rise.
Since 2021, 60% of novel therapies approved by the FDA are biotech products.
Moreover, global sales of biotech products have consistently increased since 2018, surpassing $466 billion in 2022.
Source: csdd.tufts.edu/impact-reports
🗣️ Help us spread the news:
https://x.com/triallofficial/status/1731655589191713253?s=20
#blockchainforhealth #TRL
Being data-driven vs data-informed 🤖
The term ‘data-driven’ gets thrown around a lot these days, but can we really speak of data-driven clinical research?
While it is true that advances in data science, AI, and technology have enabled more data-derived insights, the importance of stakeholder knowledge and input in clinical trials cannot be overstated.
Expert judgement, ethical considerations, and contextual factors all play a crucial part in the decision-making process.
👇🧵In this Twitter thread we take a closer look at this topic:
https://x.com/triallofficial/status/1732373504589258809?s=20
#blockchainforhealth #TRL #DeSci
The term ‘data-driven’ gets thrown around a lot these days, but can we really speak of data-driven clinical research?
While it is true that advances in data science, AI, and technology have enabled more data-derived insights, the importance of stakeholder knowledge and input in clinical trials cannot be overstated.
Expert judgement, ethical considerations, and contextual factors all play a crucial part in the decision-making process.
👇🧵In this Twitter thread we take a closer look at this topic:
https://x.com/triallofficial/status/1732373504589258809?s=20
#blockchainforhealth #TRL #DeSci